{"id":250001,"date":"2023-03-31T00:00:00","date_gmt":"2023-03-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidmd0069-biopharma-primary-biliary-cholangitis-epidemiology\/"},"modified":"2026-04-27T23:26:54","modified_gmt":"2026-04-27T23:26:54","slug":"epidmd0069-biopharma-primary-biliary-cholangitis-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0069-biopharma-primary-biliary-cholangitis-epidemiology-mature-markets\/","title":{"rendered":"Primary Biliary Cholangitis &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of primary biliary cholangitis (<abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of <abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report. In addition to forecasting incident and prevalent patient populations in these markets, we estimate the number of drug-treatment opportunities in specific lines of therapy.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts nine <abbr data-abbreviation-entity=\"5885\" title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incidence cases of <abbr title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> based on biopsy.<\/li>\n<li><abbr title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> by stage of fibrosis.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> with fatigue.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> with pruritus.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> with jaundice.<\/li>\n<li>Drug-treated prevalent cases of <abbr title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"primary\u00a0biliary\u00a0cirrhosis\/cholangitis\">PBC<\/abbr> based on the response to ursodeoxycholic acid (<abbr data-abbreviation-entity=\"7499\" title=\"ursodeoxycholic acid\">UDCA<\/abbr>).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250001","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-primary-biliary-cholangitis","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250001\/revisions"}],"predecessor-version":[{"id":281688,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250001\/revisions\/281688"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}